Search Results

“I believe not only that multiple myeloma will be a chronic illness, but also that we will see sustained complete responses in a significant fraction of patients,” predicted Kenneth C. Anderson, MD, as he described the emerging landscape in

Multiple myeloma (MM) is the second most common hematologic malignancy. It accounts for 1% of all cancers and 13% of hematologic neoplasms. The median age at diagnosis is 70 years, with 37% of patients younger than 65 years, 26% aged 65 to 74

Numerous advances have recently been made in the treatment of relapsed/refractory (R/R) multiple myeloma (MM): novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have

for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma NCCN Guidelines Insights : Multiple Myeloma, Version 3.2018 Version 3.2018 © National Comprehensive

activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma contain 2 important updates that should translate into more effective treatment with available agents. However, what is particularly exciting to Kenneth C

the express written permission of the NCCN © 2009. Disclosures for the NCCN Multiple Myeloma Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry

–outcome relationship in multiple myeloma (MM) showing that patients treated at low-volume facilities had a 22% increased risk of death compared with those treated at high-volume facilities. Provider expertise and hospital volume are overlapping, but both these distinct

Multiple myeloma (MM) is a hematologic malignancy characterized by significant bone disease; lytic lesions are present in >60% of patients at diagnosis, as are pathologic fractures, osteoporosis, and hypercalcemia. 1 Due to the frequency and

Multiple myeloma (MM) is a clinically and pathophysiologically heterogeneous disease, as evidenced by variable response to treatment and variation in survival from a few months to more than 10 years. Nationwide U.S. data show that approximately 20